How does treatment management change with a positive intramammary lymph node in the setting of a negative axilla, with the inclusion of these as N1 node in the AJCC 8th edition?
Answer from: Radiation Oncologist at Community Practice
I don’t think anything would change for management as I would treat the same RT field and a med onc would follow the same principle of using genomic assay (or phenotype) to decide about systemic treatment.
Comments
Radiation Oncologist at Confluence Health So in the patient with a positive intramammary nod...
Radiation Oncologist at Varian Medical Systems/Allegheny health network If they have positive intramammary node and negati...
Radiation Oncologist at Confluence Health No axillary "sentinel lymph node evaluation" was p...
Radiation Oncologist at Varian Medical Systems/Allegheny health network Yes, ideally sentinel node evaluation should be pe...
Radiation Oncologist at Willis-Knighton Medical Center As an addendum.
In a patient in their 70s subsequ...
Radiation Oncologist at Varian Medical Systems/Allegheny health network I would not as the absolute risk of LRR is small.&...
So in the patient with a positive intramammary nod...
If they have positive intramammary node and negati...
No axillary "sentinel lymph node evaluation" was p...
Yes, ideally sentinel node evaluation should be pe...
As an addendum. In a patient in their 70s subsequ...
I would not as the absolute risk of LRR is small.&...